Brookline analyst Leah Rush Cann downgraded MEI Pharma to Hold from Buy without a price target after the company announced it is exploring strategic alternatives. The firm says extending its current cash runway beyond December 31 hinges on the cost saving and the strategic directions MEI pursues. The analyst cites increased uncertainty to the path forward for the downgrade.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter